Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Clinical trial NCT05748834 · RECRUITING
Trial details
- NCT number
- NCT05748834
- Sponsor
- SCRI Development Innovations, LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-24
- Primary completion
- 2027-11-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.